BioCentury
ARTICLE | Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

Despite ODAC’s snub of quizartinib, Daiichi has several moves to make its 2025 cancer drug goals

May 24, 2019 9:58 PM UTC

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s goal of launching seven new cancer drugs by 2025.

While Daiichi Sankyo Co. Ltd. has traditionally focused on cardiometabolic disorders, the company has been making moves over the last three years to stake out space in oncology, including adding key R&D leaders, building out its antibody-drug conjugate (ADC) platform and striking a dozen in-licensing deals...